Oxford Biomedica plc
Company Snapshot
Company Overview
Oxford Biomedica PLC (OXB) provides manufacturing and process development services specifically tailored for pharmaceutical and biotech companies in the cell and gene therapy sector. It focuses on producing viral vectors, including adenoviral, lentiviral, and AAV vectors. Its flagship products include the Lentivector platform, inAAVate, and AdenoVate. OXB's offerings serve the pharmaceutical and biotech industries in developing and scaling cell and gene therapy products for various therapeutic uses. The firm has license agreements and partnerships with other businesses to develop potential gene and cell therapy products based on its platform. OXB operates globally, targeting markets in the cell and gene therapy industry, with facilities in Boston, U.S., and other locations in the U.K.
Financial Highlights (FY 2025)
This information is available for BCC Research members only.
Oxford Biomedica plc In News
Company's Business Segments
- Bioprocessing/ Commercial Development : This Platform segment which includes the revenue generating Bioprocessing, Process Development Activities for third parties and internal technology projects to develop new potentially Saleable Technology.
- Licence Fees & Incentives : This segment includes Fees, Incentives received from the clients for selling the Research activities.
Applications/End User Industries
- Biotechnology
- Clinical
- Vaccines
- Bioprocessing
- Cell and Gene Therapy